Published in Clin Cancer Res on August 01, 2008
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst (2010) 2.79
Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat Commun (2014) 1.42
Telomeres, lifestyle, cancer, and aging. Curr Opin Clin Nutr Metab Care (2011) 1.35
Is telomerase a viable target in cancer? Mutat Res (2011) 1.23
Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome. Oncogene (2011) 1.04
Targeting telomerase-expressing cancer cells. J Cell Mol Med (2011) 0.96
Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth. Oncogene (2013) 0.89
Immunosenescence and rheumatoid arthritis: does telomere shortening predict impending disease? Autoimmun Rev (2011) 0.83
Biology of telomeres: importance in etiology of esophageal cancer and as therapeutic target. Transl Res (2013) 0.81
Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells. PLoS One (2014) 0.79
Emerging therapeutic targets in esophageal adenocarcinoma. Oncotarget (2016) 0.75
Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma. Oncotarget (2017) 0.75
Variations in telomere maintenance and the role of telomerase inhibition in gastrointestinal cancer. Pharmgenomics Pers Med (2015) 0.75
Targeting telomerase with radiolabeled inhibitors. Eur J Med Chem (2016) 0.75
A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A (1995) 32.89
Specific association of human telomerase activity with immortal cells and cancer. Science (1994) 28.20
Telomeres shorten during ageing of human fibroblasts. Nature (1990) 23.97
Extension of life-span by introduction of telomerase into normal human cells. Science (1998) 20.48
Telomere measurement by quantitative PCR. Nucleic Acids Res (2002) 18.69
Creation of human tumour cells with defined genetic elements. Nature (1999) 16.47
Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell (1997) 13.34
A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A (1988) 11.81
Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J (1992) 10.97
A survey of telomerase activity in human cancer. Eur J Cancer (1997) 10.84
Essential role of mouse telomerase in highly proliferative organs. Nature (1998) 7.23
Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell (1999) 6.98
Telomere loss: mitotic clock or genetic time bomb? Mutat Res (1992) 6.50
Structure and variability of human chromosome ends. Mol Cell Biol (1990) 6.18
Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J (1995) 6.03
Telomeres and their control. Annu Rev Genet (2000) 4.74
Telomerases. Annu Rev Biochem (1992) 3.83
Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci U S A (1995) 3.79
Telomeric repeat from T. thermophila cross hybridizes with human telomeres. Nature (1988) 3.20
Human telomerase and its regulation. Microbiol Mol Biol Rev (2002) 3.11
Telomerase activity in the regenerative basal layer of the epidermis inhuman skin and in immortal and carcinoma-derived skin keratinocytes. Proc Natl Acad Sci U S A (1996) 2.05
Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res (1996) 1.87
Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res (1996) 1.87
Mammalian telomeres and telomerase. Curr Opin Cell Biol (2000) 1.70
Telomere-related genome instability in cancer. Cold Spring Harb Symp Quant Biol (2005) 1.69
Laser capture microdissection-generated target sample for high-density oligonucleotide array hybridization. Biotechniques (2000) 1.68
Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg (2000) 1.59
Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood (2003) 1.56
Anti-apoptotic role of telomerase in pheochromocytoma cells. J Biol Chem (1999) 1.53
Telomere maintenance by telomerase and by recombination can coexist in human cells. Hum Mol Genet (2001) 1.48
Telomeres: prognostic markers for solid tumors. Int J Cancer (2006) 1.44
Telomeres and telomerase in prostatic intraepithelial neoplasia and prostate cancer biology. Urol Oncol (2006) 1.38
Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential. Mol Cancer (2005) 1.32
Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed human cells. Oncogene (1999) 1.31
Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Mol Cancer Ther (2003) 1.26
Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. Oncogene (2003) 1.26
Telomerase regulation: not just flipping the switch. Curr Opin Genet Dev (2002) 1.24
Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res (2004) 1.21
In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer (1998) 1.15
Cyclin D1 overexpression and p53 inactivation immortalize primary oral keratinocytes by a telomerase-independent mechanism. J Clin Invest (2001) 1.14
Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991. Mol Cancer Ther (2002) 1.13
The reactivation of telomerase activity in cancer progression. Trends Genet (1996) 1.13
Chromosomal instability in Barrett's esophagus is related to telomere shortening. Cancer Epidemiol Biomarkers Prev (2006) 1.12
Telomeres, telomerase, and tumorigenesis--a review. MedGenMed (2004) 1.11
Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors. Oncogene (2002) 1.11
Growth arrest, apoptosis, and telomere shortening of Barrett's-associated adenocarcinoma cells by a telomerase inhibitor. Gastroenterology (2004) 1.10
Telomerase in human development and cancer. J Cell Physiol (1997) 1.07
Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res (2003) 1.03
Telomere dynamics, end-to-end fusions and telomerase activation during the human fibroblast immortalization process. Oncogene (1999) 1.01
Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Res (1998) 1.01
Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression. Neoplasia (2001) 1.00
Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy. Leukemia (2003) 0.93
2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells. Cancer Gene Ther (2002) 0.92
DNA index determination with Automated Cellular Imaging System (ACIS) in Barrett's esophagus: comparison with CAS 200. BMC Clin Pathol (2005) 0.92
Telomerase is active in normal gastrointestinal mucosa and not up-regulated in precancerous lesions. J Cancer Res Clin Oncol (1999) 0.90
Telomere length is a prognostic factor in neuroblastoma. Cancer (2006) 0.90
A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia. Int J Oncol (2004) 0.87
Targeting the single-strand G-rich overhang of telomeres with PNA inhibits cell growth and induces apoptosis of human immortal cells. Exp Cell Res (2004) 0.87
Telomerase inhibitors as anticancer therapy. Curr Med Chem Anticancer Agents (2002) 0.86
Zoning of mucosal phenotype, dysplasia, and telomerase activity measured by telomerase repeat assay protocol in Barrett's esophagus. Neoplasia (2004) 0.85
Telomerase, hTERT and splice variants in Barrett's oesophagus and oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol (2005) 0.84
Telomeres and their possible role in chromosome stabilization. Environ Mol Mutagen (1993) 0.82
Telomerase activity level, but not hTERT mRNA and hTR level, regulates telomere length in telomerase-reconstituted primary fibroblasts. Exp Cell Res (2004) 0.81
The implication of telomerase activity and telomere stability for replicative aging and cellular immortality (Review). Oncol Rep (1998) 0.80
Shortened telomere length in hepatocellular carcinomas and corresponding background liver tissues of patients infected with hepatitis virus. Jpn J Cancer Res (1996) 0.78
N-(4-hydroxyphenyl)retinamide activation of transforming growth factor-beta and induction of apoptosis in human breast cancer cells. Nutr Cancer (1999) 0.78
[Telomerase activity in esophageal carcinoma and lesions unstained with Lugol's solution]. Nihon Rinsho (1998) 0.77
Telomere dynamics: the means to an end. Cell Prolif (2007) 0.77
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (2008) 5.22
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem (2002) 4.94
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Multiple myeloma. Lancet (2009) 4.60
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 4.56
Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics (2002) 4.56
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A (2003) 4.47
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A (2002) 4.33
Advances in biology of multiple myeloma: clinical applications. Blood (2004) 4.13
Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res (2006) 4.11
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med (2010) 4.00
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A (2005) 3.86
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell (2007) 3.76
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood (2002) 3.73
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Telomere length, cigarette smoking, and bladder cancer risk in men and women. Cancer Epidemiol Biomarkers Prev (2007) 3.63
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood (2002) 3.62
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Accounting for haplotype uncertainty in matched association studies: a comparison of simple and flexible techniques. Genet Epidemiol (2005) 3.44
Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol (2005) 3.43
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 3.41
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A (2003) 3.30
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell (2004) 3.25
Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol (2009) 3.21
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol (2006) 3.20
Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am J Gastroenterol (2009) 3.18
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood (2009) 3.12
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res (2009) 3.05
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood (2006) 3.04
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood (2002) 3.01
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res (2002) 2.83
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst (2010) 2.79
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood (2007) 2.76
A prospective study of telomere length and the risk of skin cancer. J Invest Dermatol (2008) 2.75
Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med (2006) 2.72
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene (2002) 2.66
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood (2007) 2.65
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood (2009) 2.61
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol (2009) 2.59
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol (2010) 2.51
Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther (2009) 2.47
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol (2008) 2.45
Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer (2002) 2.42
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica (2006) 2.40
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med (2015) 2.39
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest (2013) 2.34
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol (2009) 2.32
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol (2006) 2.32
Targeted imaging of esophageal neoplasia with a fluorescently labeled peptide: first-in-human results. Sci Transl Med (2013) 2.30
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood (2012) 2.29
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood (2009) 2.28